Satsuma Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
4819 Emperor Boulevard, Suite 340, Durham, North Carolina
State of incorporation
Delaware
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 836 % -41.7%
Debt-to-equity 12.7 % +86.5%
Return On Equity -115 % -121%
Return On Assets -102 % -110%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.2M shares +5.09%
Common Stock, Shares, Outstanding 33.2M shares +5.09%
Entity Public Float 93.3M USD -41.3%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.2M shares +5.09%
Weighted Average Number of Shares Outstanding, Diluted 33.2M shares +5.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 40M USD -4.85%
General and Administrative Expense 14.4M USD +1.53%
Operating Income (Loss) -66.2M USD -17.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -64.8M USD -15.3%
Earnings Per Share, Basic -2.01 USD/shares +36.7%
Earnings Per Share, Diluted -2.01 USD/shares +36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.5M USD -8.58%
Cash, Cash Equivalents, and Short-term Investments 41.4M USD
Assets, Current 43.4M USD -48.4%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 82K USD -66.4%
Other Assets, Noncurrent 22K USD -95.8%
Assets 43.5M USD -53.6%
Accounts Payable, Current 874K USD -51.4%
Accrued Liabilities, Current 4.84M USD +19%
Liabilities, Current 5.83M USD -11.5%
Operating Lease, Liability, Noncurrent 70K USD
Liabilities 5.83M USD -12.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +95.9%
Retained Earnings (Accumulated Deficit) -222M USD -41.2%
Stockholders' Equity Attributable to Parent 37.6M USD -56.7%
Liabilities and Equity 43.5M USD -53.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD +20.5%
Net Cash Provided by (Used in) Financing Activities -500K USD -101%
Net Cash Provided by (Used in) Investing Activities 14.5M USD -28.8%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 33.2M shares +5.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.1M USD -43.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.5M USD -8.58%
Interest Paid, Excluding Capitalized Interest, Operating Activities 11K USD -74.4%
Deferred Tax Assets, Valuation Allowance 47.1M USD +45.6%
Deferred Tax Assets, Gross 47.1M USD +44.2%
Operating Lease, Liability 116K USD -51.7%
Depreciation 418K USD +3.21%
Payments to Acquire Property, Plant, and Equipment 24K USD -98.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.7M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid 130K USD -47.4%
Operating Lease, Liability, Current 116K USD -14.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -29.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD +100%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +11.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.23M USD +202%
Operating Lease, Payments 100K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 23K USD -93%
Share-based Payment Arrangement, Expense 5.56M USD +8.28%
Interest Expense 72K USD -71.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%